A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia

Clin Case Rep. 2021 Sep 15;9(9):e04533. doi: 10.1002/ccr3.4533. eCollection 2021 Sep.

Authors

Misam Zawit¹, Carmelo Gurnari^{1

2}, Simona Pagliuca^{1

3}, Hassan Awada¹, Jaroslaw P Maciejewski¹, Yogen Saunthararajah¹

Affiliations

¹ Translational Hematology and Oncology Research Department Taussig Cancer Center Cleveland Clinic Cleveland OH USA.
² Department of Biomedicine and Prevention & Ph.D in Immunology, Molecular Medicine and Applied Biotechnology University of Rome Tor Vergata Rome Italy.
³ Université de Paris Paris France.

Abstract

We report on a novel, successful, non-cytotoxic therapy to treat multiply-refractory T-LGL in an elderly patient.

Keywords: T‐cell large granular lymphocytic leukemia; decitabine; frail patients; non‐cytotoxic regimen.

© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Publication types

Case Reports

Grants and funding